NIRLAB puts a subscription spine under 908 Devices' detection portfolio
A Colorado colorimetric ban and a quantified recurring-revenue model turn the narcotics workflow into software, while $10M+ AVCAD upside waits on the Pentagon
MASS · Earnings Call · 2026-08-11
A quarter that reads as a confirmation
908 Devices' Q2 2026 numbers are the cleanest confirmation yet that its strategic transformation is landing. Revenue hit $16.1M, +23% YoY; gross margin expanded to 52% (57% adjusted, +85bps); and the adjusted EBITDA loss narrowed to under $2M, a 50% improvement. The stock had already voted: after a brutal -85.8% drawdown from the 2021 peak (MASS full-period return -78.2%), the tape has rallied roughly 50% over the last 90 days into this print. The interesting part isn't the beat — it's what's driving it.
The NIRLAB acquisition, closed May 6, moved from "strategic fit" to real commercial motion in barely 60 days. Management quantified the model for the first time: more than 35 devices sold post-close, “each with a multiyear software subscription” — Kevin Knopp, Chief Executive Officer and Co-Founder · 2026-08-11, with shipments to Colorado and California law enforcement and to customs agencies in Morocco and Iceland. The economics are stark — about a $10,000 device carrying a ~$5,000/year software subscription, a 50% recurring attach.
We believe that model, hardware, software and expert support working together can guide how we build and monetize every product in our portfolio for years to come.
That line from Kevin Knopp is the strategic pivot in one breath. Recurring revenue was 31% of total this quarter, and Joe Griffith set a target trajectory — “starting to creep up into the 30s, kind of approaching that 40% is what we aspire to.” — Joseph Griffith, Chief Financial Officer · 2026-08-11 The subscription attach is the clearest mechanism to lift recurring revenue from its ~30% baseline toward that 40% goal — the core of the company's third strategic focus, revenue durability.
A regulatory tailwind that's genuinely company-specific
The most underappreciated line of the call was about colorimetric test kits. Kevin: “Colorado's legislature voted unanimously this year to ban custodial arrest based solely on colorimetric results, and reform efforts are underway in at least 7 other states.” — Kevin Knopp, Chief Executive Officer and Co-Founder · 2026-08-11 This is precisely the kind of durable, demand-pull signal that turns a product company into a platform company — and it's a catalyst with no obvious parallel in the broader market's keyword set today.
The theme is reinforced by hardware momentum. The modernization cycle is real: 750+ FTIR devices shipped over 24 months, VipIR at 35+ units in Q2 targeting 100+ for the year, and XplorIR placements up nearly 70% over 12 months. The ProtectIR award — a $6M July order from an APAC corrections agency — shows the same playbook scaling internationally. And the portfolio is now explicitly bundled, as Kevin framed it: “our MX, our NIRLAB as well as the VipIR, it creates kind of a complete workflow for those customers.” — Kevin Knopp, Chief Executive Officer and Co-Founder · 2026-08-11
What changed vs. prior quarters
The contrast with earlier calls is sharp. In March 2026, management was still planning AVCAD inside guidance — Kevin noted “we will see an award this spring, and hence we are factoring it into some of the guidance discussion today.” — Kevin J. Knopp, Chief Executive Officer and Co-Founder · 2026-03-03 By August, the program has been pulled out of the base case entirely; the current contract "has run its course," the government is weighing commercial off-the-shelf paths like the MX908 ("the government is also considering our commercially available product due to a broader procurement reform at the Department of Defense"), and any contribution is explicitly upside. That is a real de-risking of the forecast, even if it defers a $10M+ program.
The NIRLAB narrative also evolved. At the May call, Joe Griffith framed it as “subscale today... a path that NIRLAB can be... breakeven in 2027 for adjusted EBITDA.” — Joseph Griffith, Chief Financial Officer · 2026-05-06 Today, the framing is a subscription flywheel with demonstrated U.S. demand and enterprise-scale opportunities forming in the pipeline.
The financial spine
Reported gross margin at 52% (57% adjusted) is up ~400bps YoY, aided by the Boston facility move and a favorable channel mix of U.S. state and local placements.
The balance sheet remains comfortably capitalized — $101.5M in cash and marketable securities with no debt, plus a released escrow from the desktop divestiture to Repligen. The operating leverage is showing up: adjusted EBITDA loss cut in half, and full-year guidance raised to $68-70M (21-25% growth).
Why it matters
The underlying thesis — narcotics and chemical detection modernization funded by state and local budgets — was already intact. What changed this quarter is that the subscription model became a demonstrable, quantified growth engine rather than an aspiration. NIRLAB anchors the Team leader-backed revenue mix strategy, and the Colorado legislative wave is a durable, company-specific tailwind with no direct parallel in today's broad-market keywords. If AVCAD resolves favorably — either via Smiths Detection or directly with the commercial MX908 — that's meaningful upside, but it's now optionality, not an assumption. For a small-cap still ~85% below its all-time high yet compounding from a far more durable base, that re-rating is exactly the point.